Brief: Nanobiotix Announces New NBTXR3 Data In Oncology

Nanobiotix SA

06/06/2022 06:55

June 6 (Reuters) - NANOBIOTIX SA  NANOB.PA :
    * NANOBIOTIX ANNOUNCED ON SUNDAY NEW DATA FEATURING NBTXR3
PLUS
CHEMORADIATION AND IN PREOPERATIVE SETTING SUPPORT BROAD
APPLICABILITY FOR HEAD AND NECK CANCER AND OTHER SOLID TUMOR
INDICATIONS
    * NBTXR3 DEVELOPED AS PRODUCT CANDIDATE WITH POTENTIAL TO
INTEGRATE ACROSS STANDARDS OF CARE IN ONCOLOGY, AND DATA FROM
COLLABORATOR-SPONSORED PHASE 1B/2 STUDIES ADD SUPPORT FOR
RADIOENHANCER IN COMBINATION WITH CHEMORADIATION AND IN
PREOPERATIVE SETTING
    * DATA FROM PHASE 1B/2 HEAD AND NECK CANCER STUDY IN 12
EVALUABLE
PATIENTS WITH STAGE 4 DISEASE SHOWED COMBINING NBTXR3 WITH
CONCURRENT CHEMORADIATION WAS FEASIBLE, HAD FAVORABLE SAFETY
PROFILE, PRODUCED 100% DISEASE CONTROL RATE, AND OVERALL
RESPONSE RATE OF 58.3%
    * DATA FROM PHASE 1B/2 RECTAL CANCER STUDY IN 31 EVALUABLE
PATIENTS WITH UNRESECTABLE DISEASE SHOWED COMBINING NBTXR3 WITH
CONCURRENT CHEMORADIATION IN PREOPERATIVE SETTING WAS FEASIBLE,
HAD FAVORABLE SAFETY PROFILE, ENABLED 96% OF EVALUABLE PATIENTS
TO UNDERGO R0 SURGERY, PRODUCED 100% DISEASE-CONTROL RATE, 35.5%
OVERALL RESPONSE RATE, AND 20% PATHOLOGICAL COMPLETE RESPONSE
RATE IN 25 PATIENTS WHO UNDERWENT SURGERY
    * COMPANY BELIEVES NEW DATA ADD SUPPORT FOR RADIOENHANCER IN
COMBINATION WITH CHEMORADIATION AND AS NEOADJUVANT
(PREOPERATIVE) THERAPY WITH POTENTIAL TO IMPROVE SURGICAL
OUTCOMES

        
 Source text for Eikon:  ID:nBw3sWvV9a 
 Further company coverage:  NANOB.PA  

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))